Enrolling By Invitation PHASE3 NCT07008469

Global Open-Label Extension Study of Del-desiran for the Treatment of DM1

A Global Phase 3 Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Intravenous AOC 1001 for the Treatment of Myotonic Dystrophy Type 1

Sponsor: Avidity Biosciences, Inc.

Conditions DM1 Myotonia Myotonic Disorders Myotonic Dystrophy Myotonic Dystrophy 1 Myotonic Dystrophy Type 1 Steinert Disease Steinert Myotonic Dystrophy

Interventions Del-desiran (AOC 1001)

Updated 5 times since 2025 Last updated: Feb 2, 2026 Started: Jul 25, 2025 Primary completion: Aug 31, 2030 Completion: Oct 31, 2030

A PHASE3 clinical study on DM1 and Myotonia, this trial is ongoing. The trial is conducted by Avidity Biosciences, Inc. and has accumulated 5 data snapshots since 2025. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Feb 2026 — Present [monthly]

Enrolling By Invitation PHASE3
Jan 2026 — Feb 2026 [monthly]

Enrolling By Invitation PHASE3
Oct 2025 — Jan 2026 [monthly]

Enrolling By Invitation PHASE3
Sep 2025 — Oct 2025 [monthly]

Enrolling By Invitation PHASE3

Status: Not Yet Recruiting → Enrolling By Invitation
Jul 2025 — Sep 2025 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Avidity Biosciences, Inc.

Data source: Avidity Biosciences, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aomori, Japan , Baltimore, United States , Boston, United States , Columbus, United States , Denver, United States , Durham, United States , Gainesville, United States , Houston, United States , Indianapolis, United States , Kansas City, United States and 10 more locations